Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma

BACKGROUND: The optimal number of neoadjuvant chemotherapy cycles in patients with advanced ovarian cancer is still disputed. OBJECTIVE: To evaluate the impact of the number of neoadjuvant chemotherapy cycles and role of optimal cytoreduction on the prognosis of patients with advanced ovarian cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Anna Myriam, Coada, Camelia Alexandra, Ravegnini, Gloria, De Leo, Antonio, Damiano, Giuseppe, De Crescenzo, Eugenia, Tesei, Marco, Di Costanzo, Stella, Genovesi, Lucia, Rubino, Daniela, Zamagni, Claudio, De Iaco, Pierandrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423511/
https://www.ncbi.nlm.nih.gov/pubmed/37429642
http://dx.doi.org/10.1136/ijgc-2022-004249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423511/
https://www.ncbi.nlm.nih.gov/pubmed/37429642
http://dx.doi.org/10.1136/ijgc-2022-004249

Ejemplares similares